Immunogenicity (ADA, nAbs)
Immunogenicity (ADA, nAbs)
Our laboratory provides comprehensive services for assessing immunogenicity through the development and validation of assays for anti-drug antibodies (ADA) and neutralizing antibodies (nAbs). We utilize a tiered approach to evaluate the immunogenic potential of biotherapeutics, ensuring accurate immune response assessments.
Key Services:
- Development of assays for ADA and nAbs
- Method validation for accurate immune response assessment
- The immunogenic potential of a biotherapeutic is measured using ADA testing in a tiered approach: initial screening, confirmatory, and titre experiments, with statistical analysis to support cut point calculations.
Sensitive ADA and neutralizing antibody assays using MSD technology for precise immunogenicity assessment.
Applications:
- Evaluates antigenicity of new drug candidates
- Ensures thorough investigation of immune responses
Instrumentation: We utilize a range of advanced technologies, including:
- MSD (MESO QuickPlex SQ 120MM Model 1300)
- Tecan Infinite M200 Pro and Infinite M Nano
- Agilent BioTek ELx808